S Axelsson1, M Hjorth, J Ludvigsson, R Casas. 1. Division of Paediatrics, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden. stina.axelsson@liu.se
Abstract
AIM: The balance between T helper cell subsets is an important regulator of the immune system and is often examined after immune therapies. We aimed to study the immunomodulatory effect of glutamic acid decarboxylase (GAD) 65 formulated with aluminium hydroxide (GAD-alum) in children with Type 1 diabetes, focusing on chemokines and their receptors. METHODS: Blood samples were collected from 70 children with Type 1 diabetes included in a phase II clinical trial with GAD-alum. Expression of CC chemokine receptor 5 (CCR5) and CCR4 was analysed on CD4+ and CD8+ lymphocytes after in vitro stimulation with GAD(65) using flow cytometry, and secretion of the chemokines CCL2, CCL3 and CCL4 was detected in peripheral blood mononuclear cell supernatants with Luminex. RESULTS:Expression of Th1-associated CCR5 was down-regulated following antigen challenge, together with an increased CCR4/CCR5 ratio and CCL2 secretion in GAD-alum-treated patients, but not in the placebo group. CONCLUSION: Our results suggest that GAD-alum treatment has induced a favourable immune modulation associated with decreased Th1/Tc1 phenotypes upon antigen re-challenge, which may be of importance for regulating GAD(65) immunity.
RCT Entities:
AIM: The balance between T helper cell subsets is an important regulator of the immune system and is often examined after immune therapies. We aimed to study the immunomodulatory effect of glutamic acid decarboxylase (GAD) 65 formulated with aluminium hydroxide (GAD-alum) in children with Type 1 diabetes, focusing on chemokines and their receptors. METHODS: Blood samples were collected from 70 children with Type 1 diabetes included in a phase II clinical trial with GAD-alum. Expression of CC chemokine receptor 5 (CCR5) and CCR4 was analysed on CD4+ and CD8+ lymphocytes after in vitro stimulation with GAD(65) using flow cytometry, and secretion of the chemokines CCL2, CCL3 and CCL4 was detected in peripheral blood mononuclear cell supernatants with Luminex. RESULTS: Expression of Th1-associated CCR5 was down-regulated following antigen challenge, together with an increased CCR4/CCR5 ratio and CCL2 secretion in GAD-alum-treated patients, but not in the placebo group. CONCLUSION: Our results suggest that GAD-alum treatment has induced a favourable immune modulation associated with decreased Th1/Tc1 phenotypes upon antigen re-challenge, which may be of importance for regulating GAD(65) immunity.
Authors: Leonard C Harrison; John M Wentworth; Yuxia Zhang; Esther Bandala-Sanchez; Ralph M Böhmer; Alana M Neale; Natalie L Stone; Gaetano Naselli; Julian J Bosco; Priscilla Auyeung; Maryam Rashidi; Petra Augstein; Grant Morahan Journal: Curr Diab Rep Date: 2013-10 Impact factor: 4.810
Authors: Falastin Salami; Lampros Spiliopoulos; Marlena Maziarz; Markus Lundgren; Charlotte Brundin; Rasmus Bennet; Magnus Hillman; Carina Törn; Helena Elding Larsson Journal: J Immunol Res Date: 2022-05-25 Impact factor: 4.493
Authors: Anna K E Rydén; Johnna D Wesley; Ken T Coppieters; Matthias G Von Herrath Journal: Hum Vaccin Immunother Date: 2013-10-28 Impact factor: 3.452